Renal tumour suppressor function of the BirteHoggeDubé syndrome gene product folliculin

Journal of Medical Genetics

Volumn 47, Issue 3, 2010, Pages 182-189

  Hudon, V ^a   Sabourin, S ^a   Dydensborg, A B ^a   Kottis, V ^a   Ghazi, A ^a   Paquet, M ^b   Crosby, K ^c   Pomerleau, V ^a   Uetani, N ^a   Pause, A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Cell Signaling Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN S6;

ANIMAL TISSUE; ARTICLE; BIRT HOGG DUBE SYNDROME; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; EMBRYO DEVELOPMENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY CYST; KIDNEY INJURY; KIDNEY TUMOR; LETHALITY; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY DISEASES, CYSTIC; KIDNEY NEOPLASMS; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 3; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; RIBOSOMAL PROTEIN S6 KINASES; SYNDROME; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; MAMMALIA; MURINAE; MUS MUSCULUS;

EID: 77949681085     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2009.072009     Document Type: Article

References (44)

1. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004;4(5):381-93.
2. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007;13(2 Pt 2):671s-9s.
3. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004;10(18 Pt 2):6282S-9S.
4. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977;113(12): 1674-7.
5. Toro JR, Glenn G, Duray P, et al. BirteHoggeDube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 1999;135(10): 1195-202.
6. Zbar B, Alvord WG, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the BirteHoggeDube syndrome. Cancer Epidemiol Biomarkers Prev 2002;11(4):393-400.
7. Lindor NM, Hand J, Burch PA, et al. BirteHoggeDube syndrome: an autosomal dominant disorder with predisposition to cancers of the kidney, fibrofolliculomas, and focal cutaneous mucinosis. Int J Dermatol 2001;40(10):653-6.
8. Welsch MJ, Krunic A, Medenica MM. BirteHoggeDube syndrome. Int J Dermatol 2005;44(8):668-73.
9. Khoo SK, Bradley M, Wong FK, et al. BirteHoggeDube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene 2001;20 (37):5239-42.
10. Schmidt LS, Warren MB, Nickerson ML, et al. BirteHoggeDube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001;69(4):876-82.
11. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the BirteHoggeDube syndrome. Cancer Cell 2002;2(2):157-64.
12. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in BirteHoggeDube-associated renal tumors. J Natl Cancer Inst 2005;97(12):931-5.
13. Khoo SK, Kahnoski K, Sugimura J, et al. Inactivation of BHD in sporadic renal tumors. Cancer Res 2003;63(15):4583-7.
14. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68(4):820-3.
15. Baba M, Furihata M, Hong SB, et al. Kidney-targeted BirteHoggeDube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008;100(2):140-54.
16. Chen J, Futami K, Petillo D, et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS ONE 2008;3(10):e3581.
17. Hartman TR, Nicolas E, Klein-Szanto A, et al. The role of the BirteHoggeDube protein in mTOR activation and renal tumorigenesis. Oncogene 2009.
18. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006;103(42): 15552-7.
19. Hasumi H, Baba M, Hong SB, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 2008;415(1-2):60-7.
20. Takagi Y, Kobayashi T, Shiono M, et al. Interaction of folliculin (Birt-Hogg-Dube gene product) with a novel Fnip1-like (FnipL/Fnip2) protein. Oncogene 2008;27 (40):5339-47.
21. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115(5):577-90.
22. Corradetti MN, Inoki K, Bardeesy N, et al. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004;18(13):1533-8.
23. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6(1):91-9.
24. Liu L, Cash TP, Jones RG, et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006;21(4):521-31.
25. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30(2):214-26.
26. van Slegtenhorst M, Khabibullin D, Hartman TR, et al. The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe. J Biol Chem 2007;282(34):24583-90.
27. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of BirteHoggeDube syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008;45(6):321-31.
28. Holthofer H, Virtanen I, Pettersson E, et al. Lectins as fluorescence microscopic markers for saccharides in the human kidney. Lab Invest 1981;45(5):391-9.
29. Holthofer H, Miettinen A, Paasivuo R, et al. Cellular origin and differentiation of renal carcinomas. A fluorescence microscopic study with kidney-specific antibodies, antiintermediate filament antibodies, and lectins. Lab Invest 1983;49(3):317-26.
30. Lieubeau-Teillet B, Rak J, Jothy S, et al. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998;58(21):4957-62.
31. Kondo K, Kim WY, Lechpammer M, et al. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1(3):E83.
32. Warren MB, Torres-Cabala CA, Turner ML, et al. Expression of BirteHoggeDube gene mRNA in normal and neoplastic human tissues. Mod Pathol 2004;17(8):998-1011.
33. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the BirteHoggeDube syndrome. Am J Surg Pathol 2002;26(12):1542-52.
34. Okimoto K, Sakurai J, Kobayashi T, et al. A germ-line insertion in the Birt-Hogg-Dube (BHD) gene gives rise to the Nihon rat model of inherited renal cancer. Proc Natl Acad Sci U S A 2004;101(7):2023- 7.
35. Lingaas F, Comstock KE, Kirkness EF, et al. A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum Mol Genet 2003;12(23):3043-53.
36. Bernstein J, Evan AP, Gardner KD Jr. Epithelial hyperplasia in human polycystic kidney diseases. Its role in pathogenesis and risk of neoplasia. Am J Pathol 1987;129 (1):92-101.
37. Kobayashi A, Valerius MT, Mugford JW, et al. Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 2008;3(2):169-81.
38. Robb VA, Karbowniczek M, Klein-Szanto AJ, et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177(1):346-52.
39. van Kempen LC, Ruiter DJ, van Muijen GN, et al. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 2003;82(11):539-48.
40. Li S, Takeuchi F, Wang JA, et al. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med 2005;202(5):617-24.
41. Li S, Takeuchi F, Wang JA, et al. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc Natl Acad Sci U S A 2008;105(9):3539-44.
42. Skarnes WC. Entrapment vectors: a new tool for mammalian genetics. Biotechnology (N Y) 1990;8(9):827-31.
43. Nord AS, Chang PJ, Conklin BR, et al. The International Gene Trap Consortium website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res 2006;34(Database issue):D642-8.
44. Kurban G, Hudon V, Duplan E, et al. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 2006;66(3):1313-9.